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Abstract
Transfenac, a lotion-like formulation of diclofenac, is described. It consists of pharmaceutically acceptable ingredients and
mediates the agent transport through intact skin and into the target tissues. Therapeutically meaningful drug concentrations
in the target tissue are reached even when the administered drug dose in Transfenac is below 0.5 mg/kg body weight.
Ultradeformable agent carriers, called Transfersomes, form the basis of Transfenac. These Transfersomes are proposed to
cross the skin spontaneously under the influence of transepidermal water activity gradient (see [Biochim. Biophys. Acta 1104
(1992) 226]). Diclofenac association with ultradeformable carriers permits it to have a longer effect and to reach 10-times
higher concentrations in the tissues under the skin in comparison with the drug from a commercial hydrogel. For example,
Transfenac achieves intramuscular agent concentrations between 0.5 and 2 Wg/g and 2 and 20 Wg/g at t = 12 h, depending on
the tissue depth, when it is administered in the dose range 0.25^2 mg/kg of rat body weight. A much higher drug
concentration in a hydrogel (1.25^10 mg/kg body weight) creates the drug level of only 6 0.5 Wg/g in the muscle. The drug
concentration in the rat patella for these two types of formulation is between 1 Wg/g and 5 Wg/g or 0.4 Wg/g, respectively. The
relative advantage of diclofenac delivery by means of ultradeformable carriers increases with the treated muscle thickness and
with decreasing drug dose, as seen in mice, rats and pigs; this can be explained by assuming that the drug associated with
carriers is cleared less efficiently by the dermal capillary plexus. In pigs it suffices to use 0.3 mg of diclofenac in highly
deformable vesicles per kg body weight, spread over an area of 25 cm2, to ensure therapeutic drug concentration in a 5-cm
thick muscle specimen, collected under the agent application site. When the drug is used in a hydrogel at 8 times higher dose,
the average intramuscular concentration is at least three times lower and subtherapeutic. This suggests that diclofenac in
Transfersomes has the potential to replace combined oral/topical diclofenac administration in humans. ß 2001 Published
by Elsevier Science B.V.
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1. Introduction
Diclofenac is one of the most potent and commer-
cially successful non-steroidal anti-in£ammatory
agents [1,2]. It has an annual turnover of over 1 bil-
lion US dollars, approximately 15% of which is
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achieved with the topical remedies. Around 25 mg of
the drug in a body ensure good antiphlogistic and
analgesic e¡ects. This corresponds to a therapeutic
diclofenac concentration in the plasma, or tissue to
be treated, of approximately 0.5 Wg/g tissue [2].
The nearly perfect drug absorption in the gastro-
intestinal tract is partly o¡set by the ¢rst-pass hepat-
ic biotransformation of V50%. The peak plasma
concentration of diclofenac is close to 1 Wg/ml, for
the daily dose between 100 and 150 mg, but this level
is not maintained long. Approximately 30% of the
orally administered diclofenac is excreted in the
bile, owing to the amphipathic character of the
weakly acidic drug. The remainder ¢nally accumu-
lates in the urine, with a terminal elimination half-
time of approximately 1 h [1].
The chief disadvantage of oral diclofenac admin-
istration is not the insu⁄cient bioavailability but
rather the serious side e¡ects of the drug. These ad-
verse e¡ects are mainly due to the poor agent specif-
icity, resulting from the drug binding to certain (e.g.,
prostaglandin) receptors. The primary site of such
adverse action is the gastrointestinal tract [1]. Orally
administered diclofenac is therefore poorly tolerated
and causes stomach ulcerations.
It would be desirable to reach the therapeutic drug
concentration in the target tissue [3,4] while simulta-
neously keeping the systemic and gastrointestinal
agent concentrations as low as possible. Obviously,
such a goal can only be achieved by delivering diclo-
fenac into the body via the route other than the
mouth.
For these reasons, topical injections or epicutane-
ous applications of special diclofenac formulations
were introduced. The best known is Voltaren Emul-
gel,2 developed speci¢cally for the epicutaneous ad-
ministration. Although the drug penetration depth of
Emulgel is merely 3^4 mm [4], this formulation has
reached nearly 15% of the total market to date. As
Voltaren gel normally falls short of its therapeutic
dose by the factor of 10, 1 cm under its administra-
tion site on the skin (see [3^5] for further discussion),
this medication is typically combined with oral Vol-
taren to ensure good therapeutic e¡ects.
The depth of diclofenac permeation below the skin
is limited by the relatively good drug solubility in
aqueous systems (s 1%) and fast clearance. Low
skin permeability is also an obstacle. In Voltaren
Emulgel, diethylammonium salt of the drug and sev-
eral skin permeation enhancers are used to overcome
the skin barrier [6]. This notwithstanding, the di¡u-
sive £ow of the drug monomers across the skin can-
not match the drug elimination from the subcutane-
ous tissue: the drug spill-over into the blood
circulation leaves too little drug in the target organs
for adequate stand-alone therapy [4].
It is believed that only around 10% of diclofenac
from the epicutaneously applied Voltaren Emulgel is
biologically available. The other topical diclofenac
formulations are less e¡ective by the factor of 2 [7].
In an attempt to transport an amount of the drug
that would be in the therapeutic concentration range
across the skin, diclofenac was incorporated into
phospholipid vesicles (liposomes) [1,12] without solv-
ing the problem. The probable reason for this is the
inability of conventional liposomes to cross the skin
barrier [8^10].
We have introduced special drug carriers, so-called
Transfersomes3 for the non-invasive delivery of phar-
maceuticals across the skin. These ultradeformable
drug carriers trespass the intact skin spontaneously,
probably under the in£uence of the naturally occur-
ring, but previously overlooked, transcutaneous hy-
dration gradient. The ‘moisture seeking’ (hydrotaxis)
of Transfersomes [13] permits the carrier to bring
more than 50% [14^16,19] of the epicutaneously ad-
ministered drug across the skin barrier. The process
is controllable by formulation/administration param-
eters and provides a good basis for the topical as well
as systemic therapy [16^18].
Here we report some of our results obtained using
the formulation of diclofenac in ultradeformable
vesicles, Transfenac. We argue that a single admin-
istration of the lotion-like Transfenac formulation on
the normal skin creates therapeutically meaningful
drug concentrations in the target tissues. Transfenac
hence promises to become the remedy of ¢rst choice
for the treatment of diseases of super¢cial tissues,
such as muscles or joints.
2 Voltaren Emulgel is the trademark of Novartis. 3 Transfersome, ‘carrying body’, is a trademark of IDEA AG.
BBAMEM 78137 31-8-01
G. Cevc, G. Blume / Biochimica et Biophysica Acta 1514 (2001) 191^205192
2. Materials and methods
The drug-to-lipid ratio in the proprietary vehicles,
called Transfersomes [20], used in this study was be-
tween 1/4 and 1/9. The precise value depended on the
particular formulation type, but the former compo-
sition was commonly used. This ensured that the
£exibility of the vesicle membrane was at least 5 times
higher than that of standard phosphatidylcholine
vesicles in £uid phase. This was assessed as described
in detail in [20,36]. In short, the conclusion was made
by comparing the rate of enforced vesicle transport
across a semi-permeable barrier with the pores v3
times smaller than the average vesicle diameter. The
chief requirement for the e⁄cacy of drug transfer
across the skin permeability barrier was thus ful¢lled
[16,19].
Speci¢cally, vesicles with the size in the range 100^
200 nm were prepared from soy phosphatidylcholine
(from Natterman Phospholipids (Cologne, Germany)
or Lipoid (Ludwigshafen, Germany), with the stan-
dard deviation of size distribution typically around
30%. In brief, the formulation was prepared by
suspending the lipids in an aqueous phase in which
the drug was dissolved. Su⁄ciently vigorous stirring
or other suitable kind of suspension homogenization
(e.g., sonication) was used to diminish the average
vesicle size in original suspension. Vesicles dimension
was ¢nally brought to the desired value by extruding
the suspension through 100^200 nm pore ¢lters.
The suspension pH value was between 6.8 and 7.4,
in di¡erent experiments, but here only the data
obtained with pH 7.1 þ 0.1 are reported. For refer-
ence, the apparent dissociation constant of mem-
brane bound drug is pKa = 6.1. Under the conditions
chosen, a proportion of the drug was thus non-ion-
ized and the diclofenac^vesicle association was al-
ways appreciable. Based on the results of indirect
partitioning measurements we estimate that approx-
imately 75% of diclofenac in a typical starting sus-
pension was membrane bound, owing to (partial)
charge as well as to amphipathic character of the
drug.
The test formulations contained between 4 and
10 mg diclofenac per millilitre of suspension. De-
pending on the dosage used, volumes between 3
and 75 Wl/cm2 were used. More details on the man-
ufacturing, use, and characterization of Transfenac,
together with the formulation stability data, will be
published separately.
Diclofenac in a hydrogel (Voltaren Emulgel, a
product of Novartis) was purchased from the local
pharmacy. It contained 11.6 mg/ml of diclofenac di-
ethylamine salt, together with an undisclosed amount
of 2-propanol and propyleneglycol as the skin per-
meation enhancers.
The radioactive [3H]diclofenac, custom made by
Amersham (speci¢c activity 1.2 MBq/mg (33 WCi/
mg) dry mass), was added to pre-made Transfenac
or diclofenac in a gel (Voltaren Emulgel) at least
3 days before the experiment to the ¢nal concentra-
tion of 1.8 MBq/ml; 50 WCi/ml); in one arm of the
study, [14C]diclofenac, a gift of Novartis (Basel, Swit-
zerland), was used similarly at speci¢c radioactivity
of 2 MBq/mg dry mass (1.1 MBq/ml), but with the
label attached in the upper cyclic part of the drug
molecule. Vertical axis label always identi¢es the
marker used.
2.1. Animal experiments
Animal experiments were done on NMRI mice,
Wistar rats, and common pigs. The animals were
prepared for the drug administration by manually
trimming the hair of mice and rats to the length of
maximally 2 mm, in pigs the tentative application site
was washed only, with luke warm water. Test mate-
rial was applied topically with a precision, positive
displacement glass pipette in the case of Transfer-
some suspension and with a spatula for hydrogel.
(In the former case, the liquid was applied in several
aliquots, allowing for su⁄cient drying time between
individual applications to prevent suspension drip-
ping.) Oral administration was done through a ¢ne
tube using the same Transfenac that was also used
on the skin.
Stressful or painful manipulations were always
carried out under general injection anaesthesia
(10 Wl/g body weight, containing mixture of 6 ml
0.9% NaCl, 1 ml Ketavet 100 (Parke-Davis, Berlin,
Germany) and 0.25 ml Rompun (Bayer, Leverkusen,
Germany) given i.p.), lasting approximately 30 min.
The designated application site on the animals back
or hind extremity was marked with a permanent pen
and the drug was administered as described further
in the text.
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The blood samples (V20 Wl) were taken at given
intervals by tail puncture in rodents and through a
soft-catheter located in one of the dorsal veins in the
pigs. At the speci¢ed times, the animals were killed
by a heart puncture (rodents) or by a lethal dose of
anaesthetic agent (pigs). The treated skin as well as
all the other organs of interest were excised. The
tissue and organ samples were prepared and used
for the diclofenac radioactivity counting as described
in the following paragraphs and in our previous pub-
lications [21].
The blood and tissue samples were discoloured
with 0.4 ml H2O2 and 0.2 ml HClO4 at 80‡C over-
night. Subsequently, all probes were neutralized with
0.2 ml CH3COOH. After the addition of 10 ml
Aquasol-2 (NEN-DuPont, Dreieich, Germany), the
total radioactivity of samples was determined with
a beta-scintillation counter (Berthold, Wildbad, Ger-
many).
2.1.1. NMRI mice
NMRI mice (8^12 weeks old) were transferred into
individual cages on the day of experiment and were
otherwise kept under standard conditions (normal
diet; water ad libitum; 12/12 h light/dark regime).
They received the drug-loaded lipid suspension
from a micropipette on the upper part of the back
or on the hind leg(s). The suspension was left at the
site of administration during the entire course of ex-
periment, spread without occlusion over 0.5^4 cm2.
2.1.2. Wistar rats
Wistar rats were treated similarly except in that
the drug formulation was always administered on
hind legs, covering the knee and the proximal part
of the femur muscles, spread over an area of up to
3 cm2. After killing the animals under anaesthesia,
the appropriate muscles were sliced in thin pieces by
using a pair of sharp anatomical scissors. The sam-
ples representative of the depths of 0^0.25 cm, 0.25^
0.5 cm, 0.5^0.75 cm, 0.75^1.0 cm, 1.0^1.25 cm and
1.25^1.5 cm for the 500-g rats; somewhat thinner
sections were used for the smaller rats, but always
covered all the tissue down to the bone.
2.1.3. Pigs
Pigs had a weight of approximately 15 kg and were
kept in separate boxes. They received one (at t = 0) or
two doses (at t = 0 and, where stated, t = 12 h) of the
labelled drug formulation on the ¢rst day of the ex-
periment. The administration site was on one of the
hind legs close to the knee and had an area of up to
80 cm2, for the highest dose used. Twenty-four hours
after the ¢rst drug administration each animal was
anaesthetized and a 1-cm thick sample was cut from
the treated leg (data not shown). The wound was
then taken care of surgically. On subsequent 5 days,
that is, on days 2^6, the non-labelled drug in ultra-
deformable vesicles or in a hydrogel was adminis-
tered on the contralateral leg without occlusion
once or twice daily, corresponding to the treatment
on the day 1. On the day 7, the radioactive formu-
lations were used on the same leg that was also
treated on days 2^6 with the cold drug. Twelve hours
following the last drug administration, all animals
were anaesthetized, killed and used for the measure-
ments.
Five sequential muscle samples (each V1 cm
thick) were collected under the drug administration
site. Patella from the treated knee was also excised. A
1-cm thick piece of shoulder muscle was taken as the
‘untreated muscle’ reference sample.
2.2. Biodistribution
To get the therapeutically relevant information on
the biodistribution of diclofenac in the target tissues,
muscle(s) under the application site were collected
down to the bone and sliced to individual samples.
From the speci¢c radioactivity in these slices the
drug-related penetration pro¢le of the radioactively
labelled diclofenac was ¢nally determined.
Other samples included at least two muscle sam-
ples from the sites close to the drug administration
site (typically, super¢cial and deep calf and shank
muscles), liver and bladder (with the residual urine).
2.3. Data analysis
Data analysis was done with the software package
ORIGIN (Microcal, OR, USA). Statistical signi¢-
cance was checked with Student’s t-test and consid-
ered to be granted at P6 0.05. All results give the
mean of all measured values þ standard deviation.
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3. Results
Biodistribution and some pharmacokinetic param-
eters of two Transfersomes-based suspensions, and
of one commercial, hydrogel-based formulation of
diclofenac were studied in detail. This was done us-
ing mice, rats, and pigs. Ultradeformable vesicles
were found to improve the regio-speci¢city and the
e⁄cacy of agent delivery into the body. It was pos-
sible to improve substantially the target-tissue/blood
drug concentration ratio, therapeutic drug levels in
the systemic blood circulation were also reached,
when so desired, by applying a su⁄cient amount of
the drug on intact skin in highly deformable drug
carriers.
3.1. Biodistribution
The biodistribution of the [3H]diclofenac-derived
radioactivity in mice is illustrated in Fig. 1.
Topical use of diclofenac is believed generally to
improve the regio-speci¢city of therapy but is not
always applicable. In this study the epicutaneously
administered Transfenac and Voltaren Emulgel
were seen to deliver an appreciable amount of the
drug (around 1 Wg/g) in the murine dorsum. The
proviso was that the drug dose was greater than
2.5 mg/kg body weight, which is already an excessive
agent amount.
The localization of diclofenac in the treated tissue
is formulation as well as application-site dependent.
Several drug doses were tested on the murine hind
legs to support the conjecture. The carrier-mediated
drug delivery achieves up to one order of magnitude
better performance than the use of current commer-
cial drug-in-gel formulations. This is clear especially
when the drug concentration in subcutaneous tissue
vs. applied dose is compared (see also Section 4). The
di¡erence is greater for lower doses (see Fig. 1) and
thicker tissues. For example, the relative drug con-
centration in the dorsal muscles treated with 9 mg of
the drug per kg body weight in Transfersomes is
approx. 1.9 higher than in the case of using gel-based
formulation (6.7 Wg/g vs. 3.5 Wg/g) whereas the con-
centration ratio deep in the hind legs of rats is close
to 10, when the animals are treated with approx. 0.6
mg/kg body weight The discrepancy in pigs is even
more dramatic (see Section 4).
The drug concentration in the blood is approxi-
mately 2^3 times lower at t = 12 h. In the murine
Fig. 1. (Left) Tissue concentration of diclofenac-derived 3H-radioactivity at t = 12 h after an epicutaneous application of 2.25 mg/kg
body weight (right-dashed), 4.5 mg/kg body weight (hatched), and 9 mg/kg body weight (left-dashed) of the drug in ultradeformable
vesicles, Transfersomes, on the hind thigh of mice. (Right) Biodistribution of diclofenac-derived 3H-radioactivity 12 h after an applica-
tion of 2.25 mg/kg body weight (right-dashed), 4.5 mg/kg body weight (hatched), and 9 mg/kg body weight (left-dashed) in the com-
mercial hydrogel.
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hind legs treated with 2.25^9 mg/kg body weight of
Transfenac the drug concentration is close to 5 Wg/g.
Voltaren Emulgel in the same dose range only yields
values between 0.4 and 1.3 Wg/g. This corresponds to
a relative degree of regionalization of 3.3 for Trans-
fenac and of 1 for Emulgel.
The dorsal musculature of small rodents is typi-
cally only 2^3 mm thin. Mice are therefore unsuit-
able for predicting the penetration of diclofenac into
more voluminous tissues. Hind extremities are better
suited for such studies, since they can provide sam-
ples with a thickness of 5 mm (on a mouse) or up to
25 mm (on a rat).
Consequently, the characteristic of diclofenac bio-
distribution in ‘thick tissues’ was studied with the
radiolabelled drug formulations on the rat hind
legs. The ¢rst set of corresponding biodistribution
data is shown in Fig. 2. It demonstrates that the
drug-derived radioactivity reaches the super¢cial
muscle using a hydrogel as well as using the car-
rier-based formulation, but to a di¡erent extent.
This is also illustrated in Fig. 3 which compares
the drug distribution pro¢les in the tissues under
the site of administration. When Voltaren Emulgel
is used the average drug concentration in the muscle
below the fatty layer is 0.8 Wg/g tissue, which is not
much di¡erent from the agent concentration in the
Fig. 3. [3H]Diclofenac biodistribution after the administration of 2 mg of the drug per kg body weight in highly deformable carriers,
Transfersomes (left panel ; black columns) or in a hydrogel (right panel ; open columns) on rat hind legs.
Fig. 2. [3H]Diclofenac penetration pro¢le in the rat hind-leg
muscles. Samples were taken 12 h after administering
[3H]diclofenac in ultradeformable vesicles, Transfersomes (full
symbols, left hind leg) or in a hydrogel (open symbols, right
leg) on the skin at the dose of 2 mg/kg body weight. Diclofenac
concentration in the blood is represented as a dashed line. Inset
shows the normalized pro¢le to the point where the intramuscu-
lar values become similar to those in the blood.
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blood. Conversely, the average drug concentration in
the muscle below the Transfenac-treated skin is 6.2
Wg/g, or more than 8 times higher.
A similar trend is observed when the administered
drug dose is below 2 mg/kg body weight (Figs. 4, 5
and 7). For example, the average drug concentration
in the super¢cial muscle treated with Transfenac is
14^20.5 mg/g and approximately half these values for
the deeper muscles (data not shown). In the contra-
lateral leg treated with Voltaren Emulgel the intra-
muscular concentration is around 4 mg/g near the
surface and only approximately 0.7 mg/g deep in
the muscle. This latter value is very close to the cor-
responding blood concentration level of V0.5 mg/
ml, which indicates the lack of drug delivery specif-
icity.
The results illustrated in Fig. 4 stem from measure-
ments with rats treated on one hind leg with either
0.25 mg/kg body weight of diclofenac in ultradeform-
able vesicles or, alternatively, with 0.5 mg to 0.6 mg
of the drug per kg body weight in a commercial
hydrogel. A similar drug distribution pro¢le was ob-
tained under the application site as with the higher
drug doses but Transfenac was again more regio-spe-
ci¢c than Voltaren Emulgel (see Fig. 4), especially
deep under the treated skin; this is seen from the
fact that the deep-muscle-to-blood drug concentra-
Fig. 5. Diclofenac distribution pro¢le 12 h after an epicutaneous administration of the drug in ultradeformable vesicles (full symbols,
0.1 mg/cm2) or in a hydrogel (open symbols, 1 mg/cm2). (Left) 0.75 mg/kg body weight as 14C-labelled Transfenac or 1.5 mg/kg body
weight as Voltaren Emulgel. (Right) 0.25 mg/kg body weight (labelled with 3H) in deformable carriers or 0.6 mg/kg in Emulgel on
one of the hind legs of four (left) or two (right) test rats. (Inset) The normalized drug distribution pro¢le expressed as relative di¡er-
ence of local and systemic concentrations.
Fig. 4. Biodistribution of [3H]diclofenac-derived radioactivity
after the topical administration of a small drug amount in very
deformable vesicles, Transfersomes (black columns) or in a hy-
drogel (open columns) on the hind legs of Wistar rats.
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tion ratio for Transfenac is close to 6 while for the
gel-like preparation a value near 1 is found. This
di¡erence in regio-speci¢city is commented on fur-
ther in the text.
The relative drug concentration pro¢le, normalized
with regard to the surface concentration value, is
similar near the skin surface for Transfenac and Vol-
taren Emulgel (see Fig. 3). Greater divergence is ob-
served deep in the muscle (see insets to Figs. 3 and
5). We therefore infer that the mechanism of drug
transport across the skin is di¡erent for the vesicle
and gel-based diclofenac formulations, but the prin-
ciple of agent propagation through the muscle ap-
pears to be similar in either case. We believe that
this di¡erence is due to the fact that, in contrast to
diclofenac molecules, Transfersomes are too large to
enter into the cutaneous blood circulation. The drug
from Transfersomes is consequently cleared much
less e⁄ciently by the intradermal capillary plexus al-
lowing more drug to reach the deep subcutaneous
tissues. The porcine data discussed later in this text
indirectly support such conclusion.
For obvious reasons the drug concentration is al-
ways the highest at the skin surface. The average
carrier-mediated diclofenac concentration in the
skin (726.6 þ 0.1 Wg/g), after a single epicutaneous
administration of 2 mg diclofenac per kg body
weight, is signi¢cantly higher than that resulting
from a hydrogel administration (87.7 þ 14.7 Wg/g).
This is also true for the drug concentration in fascia
(275.6 and 29.8 Wg/g) or for the diclofenac level in
the super¢cial muscle near the drug administration
site (on average: 20.5 and 4.2 Wg/g; see Figs. 2 and
3). The drug concentration in the rat patella, which is
5 Wg/g and 0.9 Wg/g for Transfenac and Voltaren
Emulgel, respectively, depends strongly on the choice
of drug vehicle as well. These conclusions can be
drawn despite the fact that the thickness of and the
drug concentration in vehicle was di¡erent for Trans-
fenac and Emulgel, taken that the administration in
either case was done non-occlusively to mimic the
therapeutic situation.
Similar di¡erences are observed when a much
smaller amount of diclofenac is used. Administering
between 0.25 and 0.75 mg diclofenac per kg body
weight (see Figs. 4 and 5) causes a 2-fold disparity
between drug concentration deep under the skin
when Transfenac or Voltaren Emulgel is used, in
favour of the former, carrier-mediated delivery. (It
should be noted that there is a large, and fairly con-
stant, di¡erence between the drug concentrations in
the patella near the treated site mediated by Trans-
fenac or Voltaren Emulgel; see Figs. 2 and 4.) The
relative advantage of Transfenac over the drug in a
hydrogel is greater deep in the tissue. Fig. 6, which
shows the results from dose ¢nding study, and there-
fore presents some gaps, illustrates this.
The above-mentioned observations suggest that ul-
Fig. 6. Intramuscular drug concentration, deduced from the [3H]diclofenac-derived radioactivity data, at two di¡erent times after the
administration of [3H]diclofenac in highly deformable vesicles (full symbols) or in a hydrogel (open symbols). Up-triangles pertain to
the super¢cial, down-triangles to the deep muscle tissue.
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tradeformable vesicles not only improve the trans-
port of diclofenac through the skin. They also carry
a higher payload into the muscles under the applica-
tion site. Near the bone, at a depth of 24 mm in the
large and at 15 mm in the small rats, the carrier-
mediated agent accumulation exceeds the serum val-
ues by a factor of 17.5 at t = 8 h and by a factor of
10^14 for the di¡erent kinds of formulations studied
at t = 12 h. For the hydrogel-based formulation the
muscle-to-blood concentration ratio near the skin is
3.8 at t = 12 h when the drug dose is 0.5 mg/kg body
weight In the deeper muscle this advantage is lost.
The regio-speci¢city also decreases with time until
the treated-muscle/blood ratio falls below the insig-
ni¢cant level of 1.5 at t = 24 h, irrespective of the
kind of drug formulation (data not shown).
The above-mentioned result is not much ^ but sig-
ni¢cantly (P6 0.05) ^ di¡erent from the value of 0.89
measured after a single peroral use of diclofenac
(data not shown). Transfenac supersedes in absolute
terms the results obtained with the diclofenac-loaded,
topically administered gel at t = 24 h and even more
so at t = 12 h (see Fig. 6). Similar observations are
made for the joints near the gel administration site.
The muscle-to-liver ratio is typically between 1 and 3
for Voltaren Emulgel and around 6 for Transfenac.
The drug concentration in the ‘treated patella’ is
greater than 2 Wg/g tissue (data not shown) and close
to 1 Wg/g tissue (Fig. 4) when the administered
Transfenac dose is 0.5 or 0.25 mg/kg body weight,
respectively. Experimental scattering is quite large
but the average concentration measured 12 h after
applying 0.5^1 mg of diclofenac per kg body weight
in a gel is signi¢cantly lower, between 0.36 Wg/g (Fig.
4) and V1 Wg/g (data not shown).
The results of our experiments with pigs, that have
a skin permeability barrier similar to that of humans
[22], support the results obtained with rats. When the
average drug concentration is calculated for a 5-cm
thick muscle under the treated site, the following
results are obtained. Local administration of Trans-
fenac gives rise to a therapeutically meaningful drug
concentration in the muscle, and sometimes even in
the patella, under the drug application site. A twice
daily administration for 6 consecutive days of 0.075
mg of diclofenac per kg body weight, followed by a
single treatment with the detectable radioactive drug,
gives concentrations of 0.433 Wg/g in the muscle and
0.088 Wg/g in the patella, 12 h after the second
[3H]Transfenac application. Skin treatment with a
single dose of 0.15 mg/kg body weight at t =312 h
raises these levels to 0.811 Wg/g in the muscle and to
0.327 Wg/g in the patella (see Fig. 7). For a dose of
2U0.150 mg/kg body weight, the value in the muscle
is 2 Wg/g and in the patella 0.163 Wg/g. An untreated
muscle contains 0.039, 0.031 and 0.047 Wg/g for the
three increasing doses, respectively. A 4- to 8-fold
higher dose (6 1.2 mg/kg body weight) of diclofenac
in a hydrogel yields a drug concentration of 0.133
Wg/g in the treated and 0.021 Wg/g in the untreated
muscle. In the latter case, the proximal patella does
not contain any drug within the experimental error.
If the topical administration of diclofenac in a gel is
complemented with an oral drug uptake of 1.2 mg/kg
body weight on the day 1, the drug concentration
measured in the treated muscle is 0.32 Wg/g while in
the untreated one 0.1 Wg/g are found.
These results indicate that even with a smaller
drug content in ultradeformable carriers there is ap-
proximately one order of magnitude higher diclofe-
nac concentration in the target tissue than using the
Fig. 7. The average radioactivity-derived drug concentration in
individual pigs tested as described in the text with the drug in
ultradeformable vesicles, Transfersomes (left panel) or in a hy-
drogel (right panel). Treated muscles (5-cm thick sample, black
columns) and their proximal patella (open columns) are com-
pared with the untreated muscles (grey columns).
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administration of commercial Voltaren Emulgel (see
Fig. 7).
In topical human therapy the painful regions are
often treated two or three times per day with a di-
clofenac-loaded hydrogel. The poor success of such
palliative therapy must be compensated with the oral
uptake of diclofenac. Transfenac provides a solution
to this problem as it generates a sustained drug re-
lease automatically.
In our experience, Transfenac only needs to be
used once or twice daily on the skin to ensure a
good therapeutic e¡ect. Results measured with the
mice treated once or twice daily with a relatively
high dose of diclofenac imply the above-mentioned
conclusion (data not shown). Related lower dose
treatment of pigs for 6 days is also compatible with
this conjecture (see Fig. 7).
3.2. Pharmacokinetics
The drug from a hydrogel or Transfenac adminis-
tered on the skin is cleared from the blood circula-
tion with a half-time of v4 h (see Fig. 8). This is
longer than the half-time value of Voltaren in hu-
mans, t1=2 = 2 h.
4. Discussion
The relative merits of diclofenac in ultradeform-
able vesicles are best judged by comparing the results
gathered with Transfenac with those obtained using
conventional formulations and/or administrations of
the drug.
4.1. Oral
A single oral diclofenac application at the dose of
V5 mg/kg body weight in a guinea-pig model, ac-
cording to the literature [3], gives v 10 times higher
plasma and 14 times higher urine concentration than
the diclofenac gel application on the intact animal
skin. The corresponding blood value falls from 1.5
to 0.5 Wg/ml over a period of 8 h. In humans treated
chronically with a dose of approximately 2 mg/kg per
day orally, the drug concentration in the blood is
around 1 Wg/ml, according to the manufacturers’
speci¢cations. In our experiments with mice, a single
oral application of 9 mg/kg body weight created se-
rum drug concentration of approximately 1 Wg/ml at
t = 12 h (see Fig. 1, right panel). Our data thus fall in
the same range as previously published results mea-
sured in di¡erent animal species.
4.2. Skin
The transepidermal £ux of diclofenac in vitro has
been calculated by Roberts and Singh [4] to be be-
tween 0.09 Wg/h per cm2 and 0.36 Wg/h per cm2,
depending on agent’s ionization state. The ionized
diclofenac passes through the rat skin in a Franz-
cell less readily (log P = 3.57U1034 cm/h) than drug
in the protonated form, that is, at low pH (log
P = 1.82U1032 cm/h). The highest reported £ux is
approximately 0.5 Wg/h per cm2.
The in vivo penetration studies described in this
work suggest that the carrier-mediated £ux of agent
through the intact rodent skin in situ is at least 10 Wg/
h per cm2, or 30^100 times higher than that gener-
ated by a more conventional drug formulation [4].
The upper limit estimate is 30 Wg/h per cm2. Such
good performance of the vesicle-based drug formu-
lation is in our opinion due to the good capability of
ultradeformable vesicles to cross the skin and thus to
carry agents into the body.
Fig. 8. The pharmacokinetics of [3H]diclofenac appearance and
elimination from rat blood circulation after an epicutaneous ad-
ministration of 0.75 mg of drug/kg body weight in highly de-
formable carriers (Transfersomes, closed circles), in a hydrogel
(open squares) or through the mouth (crossed diamonds).
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Lipid^diclofenac combinations have been tested
before in the rat model. In a study by a Japanese
group [11], 15 mg/kg body weight of diclofenac (7-
fold the dose normally taken orally by human pa-
tients) was applied on the shaved rat dorsum alone
or in combination with a large amount of hydrogen-
ated soya phospholipids (1 mg/cm2). This resulted in
intradermal drug concentrations between 12 Wg/g and
up to 60 Wg/g of the skin tissue, depending on the
total lipid concentration used (0.1^1 wt%; data not
shown). The relative bioavailability of the drug from
such formulations was rather low, however, close to
approximately 5% for the solution and 25% for the
lipid-supplemented formulations over a period of 7 h
[11]. In the experiments reported in this work, the
carrier-mediated drug concentration in rat skin was
726 Wg/g, when a 7.5-fold lower diclofenac dose was
used. Ma¡ei and colleagues also reported that the
application of liposomal diclofenac resulted in local-
ization of the drug at the site of application on rats
with slow systemic availability; however, with the
application of ultrasound pulsed drug systemic levels
could be achieved [12].
4.3. Blood and urine
A single application of V10, V3.5 or V1.3 mg/
kg body weight diclofenac, in a commercial cream,
onto the shaved but otherwise intact guinea-pig skin
reportedly causes drug concentration in the blood to
reach 0.1, 0.02 and 0.005 Wg/ml, for the three respec-
tive doses [3]. The corresponding published values
for the urine are approximately 45, 21 and 5 Wg/ml,
respectively [3]. In our experiments with the commer-
cial diclofenac gel used on the murine hind legs
(0.03 þ 0.01) Wg/ml were detected in the blood and
(1.88 þ 1.03) Wg/g in the bladder plus residual urine,
when the drug was applied at the dose of 2.25 mg/kg.
This documents the compatibility of results between
our and previous studies.
Conversely, an epicutaneous application of Trans-
fenac under the same experimental conditions gives
rise to a drug concentration of (0.37 þ 0.12) Wg/ml.
This is 10 times higher than that of a hydrogel ap-
plication. Comparable drug concentration is also
found in the urine of test animals. Both results sug-
gest that the drug delivered by means of ultradeform-
able vesicles penetrates the skin better and is elimi-
nated more slowly from the skin than when a more
conventional formulation of this drug is used for the
reason discussed later. While the rate of drug libera-
tion and biotransformation remains to be investi-
gated we believe that, ultimately, all the drug is re-
leased from highly deformable carriers that have
crossed the skin.
4.4. Muscle
Six applications of 2U1.6 mg diclofenac per day in
a gel on the guinea-pig back, according to the liter-
ature, result in the intramuscular drug concentrations
under the application site of approximately 0.24 Wg/g
[3]. In the distal muscle 0.07 Wg/g is found. This is
55% and 87% lower than in the plasma, which con-
tains approximately 0.515 Wg of diclofenac per milli-
litre of sample [3].
Singh and Roberts [4] provided the data on the
permeation of diclofenac from several aqueous drug
preparations on the skin in vivo and in vitro. These
authors have estimated the maximum reach of agent
permeation through the rat skin not to exceed 4 mm.
When diclofenac is applied on Wistar rat backs as a
solution, the concentration of this drug deep in the
muscle is hence nearly the same as in the plasma. The
corresponding local drug concentration decrease, ac-
cording to the same authors [4], is approximately
1/10 per millimetre. This corresponds to a relative
concentration of approximately 10% in the dermis,
near less than 1% in the subcutis, around 0.2% in the
super¢cial and close to 0.015% in the deep muscle
tissue.
We ¢nd that a single application of diclofenac in a
hydrogel on the rat hind leg only creates an intra-
muscular drug concentration of (0.25 þ 0.2) Wg/g
when the administered dose is close to 1 mg/kg
body weight (data not shown). Raising this dose to
2 mg/kg body weight increases the intramuscular
drug concentration to (0.5 þ 0.3) Wg/g, when a spill-
over from the contralateral leg treated with Trans-
fenac is possible, and to approximately 0.3 Wg/g in
other cases. The intramuscular concentration is
then similar to that measured in the blood, when
the drug is used in a hydrogel. It is also roughly
comparable to the value reported by Singh and Rob-
erts [4]. Using a small amount of Transfenac (0.25
mg/kg body weight) on the skin gives rise to a sig-
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ni¢cantly lower serum drug level around 0.1 Wg/ml
(see Fig. 4).
Penetration pro¢les achieved with Transfenac in
the rat model are much closer to therapists desires.
The formulation of diclofenac in ultradeformable
vesicles gets into and across the skin approximately
ten times more e⁄ciently than the drug from a hy-
drogel administered at an intermediate dose (2 mg/kg
body weight). In Fig. 3 the drug penetration pro¢le
in the latter situation is seen to extend throughout
the entire hind leg, to a total depth of 25 mm, when
Transfenac is used (see Fig. 2). Diclofenac gel brings
the majority of the drug to the depth of merely 3^4
mm.
Drug accumulation in the hind legs of rats treated
epicutaneously with Transfenac (V2 mg/kg body
weight) is not speci¢c to this kind of animal: the
results obtained in murine (see Fig. 1, left panel) or
rat (see Fig. 2) hind-leg muscles are semi-quantita-
tively similar. Extrapolation to bigger animal species,
including humans, is therefore reasonable and is jus-
ti¢ed by the results of experiments on pigs.
4.5. Joint
Radermacher and colleagues have applied diclofe-
nac onto one knee and a placebo gel onto the other
knee of humans [5]. The resulting drug accumulation
in the synovial £uid was then concluded to stem
mainly from the systemic blood supply. High relative
drug concentrations in the smaller animal joints (3
Wg/g), or in the synovial £uid of the repeatedly
treated human ¢nger and wrist (V0.8 Wg/ml) [3],
are thus likely to be due to the short di¡usion dis-
tances in such tissue specimen. The data reported by
Radermacher should hence be compared with the
result of our measurements with the rat patella,
which contains (5.05 þ 0.07) Wg of diclofenac per
gram tissue, after a single epicutaneous Transfenac
application. Our value exceeds by the factor of 5 the
concentrations in the systemically treated (distal)
knee (0.92 þ 0.08) Wg/g or muscle (V0.75 Wg/g) of
the same test rat. In the treated knee the Transfe-
nac-derived drug concentration is also one order of
magnitude higher than in the blood. This excludes
the possibility of signi¢cant drug in£ux from the sys-
temic blood circulation into the treated knee as the
reason for the high drug concentration in the joint.
Similarly favourable results are obtained in pig
patella after the topical administration of Transfe-
nac, the speci¢c drug concentration being between
0.09 and 0.36 Wg/g.
4.6. Alternative formulations
Diclofenac to date was chie£y employed orally,
even for the treatment of the well-localized patholog-
ical states and despite the systemic side e¡ects of
the drug. The introduction of Volteren Emulgel
was therefore important and successful commercially
but alternative formulations are now being
sought.
For example, steroidal and non-steroidal anti-in-
£ammatory drugs, including diclofenac, were formu-
lated in a submicron emulsion. The latter consisted
of approximately 100 nm large oil droplets [23] and
were tested in the somewhat questionable [24] carra-
geenan-induced paw edema rat model. In such test
diclofenac in submicron emulsion proved to be 40%
more active than standard Voltaren Emulgel.
Diclofenac hydroxyethylpyrrolidine (DHEP) was
incorporated in a plaster [35], containing 180 mg
DHEP in an auto-adhesive medicated gauze pad of
standard dimensions (10U15 cm2). The steady-state
measurements with such pad on animals indicated
the sustained release (12 h) of the drug [7] with an
estimated absorbed dose of 5^10 mg per application;
this corresponds to a bioavailability of 2.5^5.5% [7]
which is not su⁄cient for the successful treatment of
all kind of diseases sensitive to nonsteroidal antiin-
£ammatory agents [25,35].
DHEP plasters were used twice daily (at 08:00 and
20:00 h) for 4 consecutive days by eight volunteers
su¡ering from monolateral knee joint e¡usion [25].
Plasters were left on the a¡ected area until the fol-
lowing application or for 12 h the 5th day. Venous
blood samples were collected immediately before the
¢rst dose and 1, 4 and 8 h after the ninth application.
Synovial £uid (SF) from the a¡ected knee joint was
collected at the beginning of the study and at 4 h
after the ninth DHEP plaster application. Un-
changed diclofenac was measured in plasma and SF
by means of a gas liquid chromatography^mass spec-
trometry technique. Low but durable levels of diclo-
fenac were obtained at each collection after dosage in
plasma. Diclofenac was detectable at somewhat high-
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er concentration in SF at the fourth hour of the
ninth application [25].
Impeding the skin barrier increases the propensity
for the drug permeation across the skin. This was
demonstrated in a study in which a total of 120 pa-
tients, with moderate to severe pain, due to localized
rheumatic or traumatic conditions, were randomly
allocated to receive ultrasonic sessions three times
weekly for 4 weeks. Voltaren Emulgel or regular
gel was used as coupling medium [26]. The physi-
cian’s overall assessment of therapeutic e⁄cacy re-
vealed that a satisfactory result was achieved in
86% of Voltaren Emulgel-treated patients compared
with 76% of patients receiving regular gel (P6 0.05).
Tolerability was good or excellent in over 95% of
patients in both treatment groups [26].
4.7. Adverse side e¡ects of the drug
The side e¡ects of diclofenac, especially in the gas-
trointestinal tract, are often serious. For the period
between 1983 and 1991, for example, 98 adverse drug
reactions to topical nonsteroidal anti-in£ammatory
agents were reported by the Spanish pharmacovigi-
lance organization [28]. Eleven general reactions,
such as duodenal ulcer, gastrointestinal bleeding, di-
arrhoea, dyspnoea, facial oedema, aggravation of
bronchospasm, and angioedema were described.
Most commonly gastrointestinal (39%) and cutane-
ous (20%) adverse events were reported. The ratio of
gastrointestinal to non-gastrointestinal reactions to
diclofenac was higher in the case of slow-release en-
teric-coating diclofenac than in the case of plain di-
clofenac (P = 0.037). Four cases of upper gastrointes-
tinal haemorrhage, resulting from the cutaneous
application of diclofenac (Voltaren Emulgel), were
also reported by Zimmerman and colleagues [32].
Three of the patients had used the medication three
times daily for at least 2 weeks over a large area
before the onset of bleeding. In two cases a peptic
ulcer was identi¢ed retrospectively, and the haemor-
rhage was massive enough to necessitate blood trans-
fusions. Therefore, diclofenac should be used pru-
dently in patients with a history of peptic ulcer [32].
In our expectation Transfenac, when administered
directly onto a diseased site in a small but su⁄cient
quantity, will cause less side e¡ects, if any, than the
currently available diclofenac formulations. This
should partly be due to the more favourable drug
biodistribution from the carriers that concentrate
the agent in the tissue to be treated. Phospholipids,
and especially phosphatidylcholine, are also known
to improve the safety of their co-applied agents,
when the latter are surfactant-like [33]. Moreover,
the co-applied lipids are likely to minimize the dan-
ger of allergic contact dermatitis that may be induced
by topical diclofenac [30].
We therefore expect that the toxicity and the side
e¡ects of diclofenac in vivo will be diminished in the
presence of ultradeformable vesicles. Such an in-
crease in the agent safety was already documented
for lidocaine in corresponding carriers [31].
4.8. Transfenac and carrier safety
When applied on the intact skin, phospholipid sus-
pensions are not detrimental to the skin. On the con-
trary, certain phospholipid preparations even seem to
improve the hydration (and thus the optical appear-
ance) of aged skin. Phospholipid suspensions are also
non-irritating to the skin, at least up to the degree of
20% degradation [29].
Transfenac will be applied in a quantity (9 50 mg)
that will not exceed the total amount of this drug
used currently parenterally (9 75 mg/injection) or or-
ally (9 150 mg/day); the daily dose of Transfenac for
humans should actually be lower: 9 25 mg and prob-
ably even 9 10 mg. Total amount of the phospholip-
id placed on the skin in the form of Transfenac,
consequently, is unlikely to exceed 1 g/day in most
cases. This is only 20% of the phospholipid quantity
that is infused daily in the form of Lipofundin or any
other comparable parenteral formulation of such lip-
id. It is also less than 20% of the natural variability
of phosphatidylcholine concentration in the plasma
for average healthy subjects [27]. Based on these
data, Transfenac is expected to be a very safe prod-
uct.
5. Conclusions
In animal experiments, the diclofenac lotion based
on ultradeformable vesicles, Transfenac, has proven
to be superior even to the best commercial diclofenac
gel for the topical administration. When used in a
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reasonable dose range in mice, Transfenac was
shown to be at least 5 times more potent and signi¢-
cantly more site-speci¢c than the ‘competing’ topical
diclofenac formulations. The relative improvement is
a¡ected by the skin/muscle-weight ratio, which is 1/8
for mice and makes the murine model suboptimal for
the prediction of therapeutic e⁄cacy of epicutane-
ously applied diclofenac. In rats, a single epicutane-
ous application of 2 mg of diclofenac per kg body
weight in highly deformable carriers produced at
least 4 times higher drug concentration in the treated
muscles than a drug-loaded hydrogel.
Agent concentration in distal muscles or in serum
is lowered by using a smaller agent amount, but
more so with Transfenac than with the diclofenac
loaded hydrogel. The e¡ect is more pronounced for
the large than for the small animals.
Diclofenac from ultradeformable vesicles can pen-
etrate deep into the soft tissue under the drug appli-
cation site. This is not observed when the drug is
used in a gel (see Figs. 4^7), unless special treatment,
such as sonophoresis [34], is used. The reach of the
carrier-associated agent may therefore exceed by
more than one order of magnitude the maximum
agent penetration from the commercial Diclofenac-
loaded gel. Ultradeformable vesicles even can bring a
therapeutic quantity of diclofenac into the treated
knee with reasonable reproducibility.
The relative advantage of using Transfenac instead
of the more conventional diclofenac gel increases in
the low dose range. This trend seems to increase with
decreasing number of the drug administrations. Both
are likely to be due, at least partly, to the sustained
release of diclofenac from the carriers deposited into
the subcutaneous tissue.
Diclofenac lotion comprising ultradeformable
vesicles, Transfersomes, combines the safety of the
conventional diclofenac formulations for the topical
administration with a high or even improved e⁄cacy.
The latter matches that of the best available oral
preparations of such drug. This suggests that the
simple-to-use, topical Transfenac formulations have
the potential to replace oral therapy with diclofenac.
We believe that such novel formulations will compete
successfully with the combined oral/topical treatment
of rheumatoid disease.
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